Althrocin

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Althrocin

Property Description
Active ingredient Erythromycin
Form Tablet, Capsule, Suspension (Oral)
Pharmacological class Macrolide Antibiotic
Common use Systemic Bacterial Infection
Origin Semisynthetic

What Type of Medicine is Althrocin?

Althrocin is a prescription-only medication whose active ingredient is Erythromycin, formally classified as an antibiotic belonging to the macrolide class of antibacterial agents. This classification establishes its fundamental purpose: to combat and control illness caused by susceptible bacterial infections. The medication is recognized globally for its role in antimicrobial therapy and is designed for systemic use, meaning it is absorbed internally to act throughout the body.

The macrolides function primarily by binding to the 50S ribosomal subunit of susceptible organisms, thereby inhibiting protein synthesis. This mechanism is clinically recognized for effectively stopping the bacteria from growing and multiplying, preventing the infection from worsening and aiding the patient’s immune system in clearing the pathogens.

Composition and Origin: Is Erythromycin a Natural or Synthetic Compound?

The compound Erythromycin is designated as a semisynthetic substance because it is derived from a naturally occurring source: the bacterial strain Saccharopolyspora erythraea. Althrocin is a single-ingredient product utilizing this compound. For oral preparations, the active ingredient is frequently formulated as a stabilized salt, such as Erythromycin stearate, or other esters like the ethylsuccinate. These specific chemical forms are utilized to protect the compound from breakdown by stomach acid, ensuring reliable absorption into the bloodstream for effective systemic distribution.

Physical Forms of Althrocin for Systemic Use

Althrocin is available for oral administration in several standardized pharmaceutical preparations, most commonly presented as film-coated tablets, capsules, or an oral suspension. The availability of the liquid suspension form is particularly useful, allowing for accurate and flexible dosing, especially for pediatric patient groups or individuals who have difficulty swallowing solid medication. All these forms are designed for the oral route of administration to achieve the necessary systemic concentration required to address bacterial infections throughout various tissues and organs.

Regulatory References

  1. Erythromycin Label (DailyMed)
  2. Erythromycin (MedlinePlus)

What side effects are possible with Althrocin?

Possible Side Effects and Safety Information

Althrocin (erythromycin) is associated with a range of adverse reactions, with the majority of reported events affecting the gastrointestinal system.

Adverse Reactions by System-Organ Class

Classification Common Reactions Serious/Clinically Significant Reactions
Gastrointestinal Nausea, vomiting, abdominal pain, diarrhea. Severe diarrhea (which may be a sign of Clostridioides difficile-associated diarrhea), pseudomembranous colitis.
Hepatobiliary Elevated liver enzymes. Cholestatic hepatitis, hepatic dysfunction, liver failure (rare).
Cardiac Not common QT interval prolongation, Torsade de Pointes (a potentially fatal heart rhythm disorder).
Immune System/Skin Rashes, hives. Anaphylaxis, Stevens-Johnson syndrome (SJS), Toxic Epidermal Necrolysis (TEN).

Warnings and Safety Considerations

The most serious safety concerns are associated with the risk of cardiotoxicity and hepatotoxicity. Althrocin use is linked to the prolongation of the QT interval, which necessitates caution in patients with pre-existing heart conditions or uncorrected electrolyte imbalances (low potassium or magnesium).

Due to its mechanism as an inhibitor of the CYP3A4 enzyme, a major drug interaction pathway, Althrocin is contraindicated with specific medications (e.g., cisapride, pimozide, and certain statins like lovastatin or simvastatin) to prevent life-threatening increases in concentration. Use in patients with existing liver impairment requires caution. In the pediatric population, a risk of Infantile Hypertrophic Pyloric Stenosis (IHPS) has been observed in neonates treated with erythromycin, requiring careful monitoring for vomiting and feeding intolerance. Elderly patients may be more susceptible to certain effects, including hearing loss and heart rhythm abnormalities.

Overdose and Emergency Response

Overdose and When to Seek Help for Althrocin

Official regulatory documentation states that an overdosage of Althrocin (Erythromycin) requires immediate medical attention due to the potential for severe and life-threatening complications.

Documented Overdose Manifestations Officially Described Severe Outcomes
Acute, severe gastrointestinal symptoms (nausea, vomiting, diarrhea). Life-threatening ventricular arrhythmias, including QTc interval prolongation, Torsades de Pointes, and cardiac arrest.
Transient hearing loss (ototoxicity) documented with high exposure levels. Central Nervous System effects such as seizures and confusion.

Emergency Action and Management Mandates

Regulators explicitly require individuals to seek emergency medical attention immediately upon confirmed or suspected overdosage. Management is strictly symptomatic and supportive because no specific antidote is known for erythromycin. Furthermore, official labeling states that the drug is not effectively removed from the body by procedures such as hemodialysis or peritoneal dialysis. Due to the critical risk of cardiotoxicity, continuous ECG monitoring is an essential requirement of medical care. Special consideration is advised for patients with existing impaired hepatic function and the elderly, who may be more susceptible to serious outcomes.

Therapeutic Uses of Althrocin

Althrocin, containing the active ingredient erythromycin, belongs to the macrolide class of antibiotics. Its therapeutic domain is applied across domains where additional symptomatic support is needed and is relevant for easing conditions presenting with systemic or localized discomfort.

Erythromycin is indicated in the management of various infections. These condition categories are relevant in conditions characterized by periods of heightened symptoms and commonly include upper and lower respiratory tract infections, skin and skin structure infections, pertussis (whooping cough), and diphtheria. It is also relevant in managing certain infections in patients with specific sensitivities.

Its application may assist with managing symptom clusters that may become intense or disruptive, and is used in settings marked by temporary physiological imbalance. This support contributes to improved comfort during periods of heightened symptoms. The general patient benefit is that the treatment contributes to easing the overall symptom load associated with the condition.

Quick Fact: supports general well-being during symptomatic phases.

Its application is relevant when supportive symptom management is appropriate and assists with maintaining functional stability during periods of heightened symptoms.

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Althrocin — Official Regulatory Information

Althrocin, containing the active ingredient erythromycin, is defined by regulatory agencies as acceptable for use in adults and children to treat susceptible bacterial infections, with specific official restrictions for certain populations and co-administered medicines.


Contraindicated Populations (Absolute Ban) Eligibility-Related Restrictions
Patients with known hypersensitivity to erythromycin or other macrolide antibiotics. Hepatic Impairment: Use requires caution due to the drug’s primary excretion via the liver.
Individuals with a history of QT prolongation or ventricular arrhythmia (Torsades de pointes). Renal Impairment: Caution is needed in elderly patients due to increased risk of ototoxicity (hearing loss).
Patients taking specific, prohibited concomitant medications, including Terfenadine, Astemizole, Cisapride, Pimozide, Ergotamine, Dihydroergotamine, Lovastatin, or Simvastatin. Infants: Use carries a specific, labeled warning regarding the potential risk of Infantile Hypertrophic Pyloric Stenosis (IHPS), particularly in the first 14 days of life.
Patients with uncorrected low potassium or magnesium levels. Pregnancy/Lactation: Permitted only if clearly needed; use during breastfeeding requires monitoring of the infant for adverse effects.

Official regulatory documents establish absolute non-eligibility through explicit contraindications concerning severe cardiac risks and the concurrent use of specified co-medications. Use is classified as conditional, requiring caution, for patients with impaired organ function (liver/kidney) or those in vulnerable age groups.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section summarizes the official interaction profile of Althrocin (erythromycin), based strictly on government regulatory documents.

Interaction Scope and Risk

Althrocin is an inhibitor of the CYP3A enzyme system, which is a primary mechanism for numerous clinically significant interactions. Co-administration with drugs primarily metabolized by CYP3A may cause elevated concentrations of the concomitant drug, increasing the risk of adverse effects. This includes, but is not limited to, certain statins (e.g., Simvastatin, Lovastatin, Atorvastatin) and specific calcium channel blockers.

Contraindicated and High-Risk Combinations

Regulatory agencies prohibit the use of Althrocin with certain agents due to the high risk of serious cardiac events, including drugs such as Cisapride and Pimozide. Other combinations carry a significant pharmacodynamic risk, such as increased QT prolongation when co-administered with other medicines that share this effect.

Other Clinically Relevant Interactions

  • Oral Anticoagulants: Co-administration may increase the anticoagulant effect, requiring close monitoring, particularly in the elderly population.
  • Digoxin: Erythromycin can elevate Digoxin serum levels.
  • Theophylline: The drug's serum levels may decrease when administered concurrently with Althrocin.
  • Verapamil: Co-administration has been associated with adverse events, including hypotension.
  • Food: To optimize drug absorption, Althrocin is often taken in the fasting state.

Mechanism of Action

Mechanism of Action: How Althrocin Works

Targeting the Bacterial Protein Factory

Althrocin (Erythromycin) works by binding to a specific site on the 50S subunit of the bacterial ribosome, which is the cell's machinery for synthesizing proteins. This interaction specifically blocks the exit tunnel required for new proteins to be released, acting as an inhibitor of translocation and immediately arresting the elongation of polypeptide chains.

Arresting Proliferation and Growth

The primary physiological consequence of inhibiting protein synthesis is the cessation of bacterial replication and growth, a state known as bacteriostasis. By preventing bacteria from synthesizing the essential components needed for survival and cell division, Althrocin limits the exponential increase of the microbial population. This action results in a static bacterial population, creating an environment where host defenses can act on the non-replicating bacterial population.

Constraints on Mechanistic Efficacy

The effectiveness of this mechanism is governed by constraints, including the bacteria's ability to evolve defense strategies. Some bacteria limit Althrocin's binding by enzymatically modifying the ribosomal target site, while others utilize specialized efflux pumps to actively transport the drug out of the cell. These mechanisms prevent the drug from reaching the effective concentration required to maintain bacteriostasis.

Dosage and Administration Information

Official Administration Guidelines for Althrocin (Erythromycin)

Althrocin, containing the active ingredient erythromycin, is administered exclusively via the oral route as tablets, capsules (delayed-release), or oral suspension. The instructions below outline the standard usage protocols.


Standard Dosing and Frequency

Standard adult dosing regimens for oral use typically involve divided doses, such as 250 mg four times daily (QID), 333 mg three times daily (TID), or 500 mg twice daily (BID). The maximum recommended daily dose for managing severe infections is limited to 4 grams (4000 mg) per day.

Course Duration: The medication must be taken for the full prescribed duration. This period is variable depending on the infection but often requires a minimum of 10 days for certain bacterial infections to ensure the completion of the therapeutic course.

Administration Rule General Administration Instructions
Timing Relative to Meals For optimal systemic absorption of some forms (Base/Stearate), take on an empty stomach (e.g., 30 minutes to 2 hours before meals). Other forms, such as Erythromycin Ethylsuccinate, may be taken without regard to food.
Dosage Form Integrity Delayed-release tablets or capsules must be swallowed whole and must not be crushed, broken, or chewed.
Oral Suspension Prep Liquid suspension must be shaken well before each dose and measured accurately using a proper dispensing device.
Missed Dose If a dose is missed, take it as soon as remembered. However, do not take two doses at once to compensate for the skipped dose.

Population-Specific Usage

Dosage for pediatric patients is determined based on body weight, typically calculated at 30 to 50 mg/kg/day in equally divided doses. For adults with severe renal impairment (reduced kidney function), the total daily dose may need to be limited, often to a maximum of 1.5 grams.

Recent Clinical Evidence

Research Evidence / Overview of Studies

A. Efficacy in Chronic Pain

Clinical trials explored whether Drug X examined whether a change in pain measures occurred by investigating inflammation-related measures. The most recent meta-analysis assessed changes in pain scores over six months. Studies assessed the safety profile and research evaluated its potential as an initial therapy.

B. Combination Therapy

Research investigated whether combining Drug X with Drug Y evaluated patient outcomes. One large study reported a difference in effect magnitude of the combination compared to Drug X alone. The study did not offer guidance on clinical implementation.

C. Side Effects and Safety Profile

Observations were made regarding the incidence of serious side effects. While studies evaluated potential liver impact, no major complications were reported in the data reviewed. Research identified considerations related to the use in populations with severe kidney disease.


Note on Interpretation: This section is a descriptive summary of research activities and findings. The presence of studies investigating a topic does not guarantee effectiveness or suitability. All clinical decisions regarding treatment, combinations, or individual suitability must be made by a qualified healthcare professional.

Frequently Asked Questions (FAQ)

Common questions about Althrocin (FAQ)

Q: What should I do if I accidentally miss a dose of Althrocin?

Official guidance suggests taking the missed dose as soon as it is remembered. However, if it is nearly time for the next scheduled dose, the missed dose is generally skipped, and the regular schedule is continued. Official information specifically warns against taking a double dose to compensate for a skipped dose.


Q: How long does a typical course of Althrocin treatment last?

The official duration of Althrocin treatment is dependent on the type and severity of the bacterial infection being treated. The full length of the course is decided by the prescribing healthcare provider, but regulatory treatment guidelines often specify courses ranging from 7 to 14 days for many common infections.


Q: Does Althrocin cause liver damage?

Official safety information for Althrocin (erythromycin) includes warnings about potential liver impact, known as hepatotoxicity. This can involve issues like increased liver enzymes or cholestatic hepatitis. Symptoms such as yellowing of the skin or eyes (jaundice) should be reported to a healthcare professional immediately.


Q: Should I swallow the tablet whole, or can I chew/crush it?

Regulatory instructions state that certain forms of Althrocin, such as delayed-release capsules and tablets, must be swallowed whole without crushing or chewing. This is important for the medication to work as intended and to protect the active ingredient. Standard film-coated tablets should also generally be swallowed whole with water.


Q: Why does Althrocin cause hearing loss in the elderly?

Official information indicates that Althrocin is associated with a risk of ototoxicity (hearing loss). This risk may be increased in older patients, particularly those with reduced kidney function, and in individuals receiving high doses. This effect has been observed to be reversible once the medication is discontinued.


Q: Can Althrocin affect my birth control pills?

Regulatory documents mention that erythromycin may interact with certain types of hormonal contraceptives, specifically those containing estrogen. This interaction could potentially reduce the contraceptive's effectiveness. Due to this potential interaction, a non-hormonal back-up method may be recommended; specific advice should be obtained from a healthcare professional.


Q: Is it safe to drink alcohol while taking Althrocin?

Official health agency information generally advises caution regarding alcohol consumption while using Althrocin. Drinking alcohol during treatment may potentially increase the risk of experiencing common gastrointestinal side effects. Individuals should consult their healthcare professional for specific guidance.


Q: What is the risk of taking Althrocin during pregnancy?

Official safety data indicates that Althrocin is often considered acceptable for use during pregnancy when a clear need exists. It is typically prescribed only if the potential benefit outweighs the potential risk. Monitoring by a healthcare professional is necessary when used during pregnancy.

How should Althrocin be stored and disposed of?

How to Store and Dispose of Althrocin?

Althrocin (erythromycin) must be stored according to regulatory specifications to ensure stability and safety. The solid oral forms must be kept at controlled room temperature, typically 20 C to 25 C (68 F to 77 F), and protected from excess heat, light, and moisture.

Storage and Handling

  • The medication must remain in its original, tightly closed container.
  • The oral suspension form must not be frozen. If reconstituted, it must be discarded after the time period specified on the label.
  • As a safety measure, Althrocin must always be stored out of the sight and reach of children.

Disposal Instructions

Official guidance requires that unused or expired Althrocin be disposed of according to local regulations or a formal drug take-back program. The product must not be flushed down the toilet or disposed of in household waste unless specifically authorized by a national health authority.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Althrocin found in:

A-Z Index: